Evaxion Biotech (EVAX) Corporate presentation summary

AI-Immunology platform and pipeline

• AI-Immunology combines models for target discovery, antigen design and vaccine development, with work spanning cancer, infectious diseases and autoimmune concepts.

• Pipeline includes EVX-01 for advanced melanoma, EVX-04 for acute myeloid leukemia, EVX-05 for glioblastoma, and infectious-disease candidates EVX-B1 through EVX-B4 and EVX-V1.

• EVX-01 is listed with a liposomal/peptide modality and a pembrolizumab supply agreement with MSD; EVX-B2 mRNA is being developed with Afrigen for low- and middle-income countries.

Staphylococcus aureus vaccine

• EVX-B1 combines five vaccine components, including fusion proteins with LukE, Hla, aureolysin and protein A, and uses CAF®01 adjuvant to induce a Th1/Th17-type response.

• In a lethal USA300 mouse sepsis model, EVX-B1 produced highly significant protection versus adjuvant or buffer controls (p<0.0001); it also reduced abscess burden in a skin infection model (p<0.0001).

• Immunized mice that survived lethal challenge cleared infection from the heart, spleen and kidneys; antibody titers persisted up to 46 weeks, and all mice given a week-48 booster survived challenge at week 50.

• Both fusion proteins showed protection in a minipig surgical-site infection model, and minipig immune blood had in-vitro bactericidal activity against S. aureus.

Neisseria gonorrhoeae vaccine

• EVX-B2 fuses two EDEN-identified antigens, Tpc and FtsN; both targets were reported present in all 1,200 available genomes, with protein expression confirmed in representative clinical isolates.

• In mice, EVX-B2 reduced vaginal bacterial burden and accelerated clearance, with no detectable bacteria by day 7 versus persistent infection through day 10 in adjuvant-only controls (AUC p=0.0029).

• Immune sera killed 100% of 50 clinically relevant strains in vitro; sera from 76 patients with disseminated gonococcal infection recognized the vaccine antigens.

• The mRNA formulation induced higher IgG titers than the protein formulation and showed similar performance in a vaginal challenge model; development with Afrigen targets the LMIC market.